A comparison of two cohort studies evaluating the safety of cisapride: Prescription-event monitoring and a large phase IV study

European Journal of Clinical Pharmacology

Volumn 52, Issue 2, 1997, Pages 87-94

  Wager, E ^a   Tooley, P J H ^a   Pearce, G L ^b   Wilton, L V ^b   Mann, R D ^b  

^a Janssen Cilag Ltd   (United Kingdom)

^b DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

adverse drug reactions; Cisapride; pharmacovigilance; post marketing surveillance; Prescription Event Monitoring

Indexed keywords

ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; CISAPRIDE; MACROLIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; ATAXIA; BACKACHE; CHILD; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERHIDROSIS; INFANT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; URINARY DYSFUNCTION; URTICARIA; VERTIGO;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CHILD; CHILD, PRESCHOOL; CISAPRIDE; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PIPERIDINES; PRESCRIPTIONS, DRUG;

EID: 0030920299     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050255     Document Type: Article

References (20)

1. Committee on Safety of Drugs (1971) Report for 1969 and 1970. HMSO, London
2. Rawlins MD, Jefferys DB (1993) United Kingdom Product Licence applications involving new active substances. 1987-1989: their fate after appeals. Br J Clin Pharmacol 35: 599-602
3. Baber NS, Smith RN (1993) Clinical trials. In: Griffin J, O'Grady J, Wells F (ed) The textbook of pharmaceutical medicine. Queen's University, Belfast, pp 406-409
4. Mann RD, Rawlins MD, Fletcher P, Wood SM (1992) Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Safety 1: 19-23
5. Inman W, Pearce G (1993) Prescriber profile and post-marketing surveillance. Lancet 342: 658-661
6. Voss S, Harris F (1994) Postmarketing surveillance. BMJ 309: 194
7. Vandenberg M (1994) Postmarketing surveillance is not used to promote products. BMJ 309: 608
8. Inman WHW (1994) Postmarketing surveillance: avoid promotional studies. BMJ 309: 608-609
9. Amery WK (1994) Post-marketing drug safety management: a pharmaceutical industry perspective, Int J Risk Safety Med 5: 67 270
10. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD (1992) Review of company postmarketing surveillance studies. BMJ 304: 1470 1472
11. Mann RD (1994) Epidemiologic study systems: Prescription-Event Monitoring in the UK. Southampton Med J 10: 12 17
12. Inman W, Kubota K, Pearce G, Wilton L (1993) PEM Report Number 8. Cisapride. Pharmacoepidemiol Drug Safety 2: 445 471
13. Heading RC & the Dyspepsia Study Group (1995) Upper gastrointestinal symptoms in general practice: a multicentre UK study. J Drug Develop Clin Pract 7: 109 117
14. MeCallum R (1991) Cisapride: a new class of prokinetic agent. Am J Gastroenterol 86: 135-149
15. Wiseman LR, Faulds D (1994) Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 47: 116 152
16. Olsson S, Edwards IR (1992) Tachycardia during cisapride treatment. BMJ 305: 748 749
17. Inman WHW, Kubota K (1992) Tachycardia during cisapride treatment. BMJ 305: 1019
18. Committee on Safety of Medicines (1995) Cisapride (Prepulsid, Alimix) interaction with ketoconazole and cardiotoxicity. Curr Prohl Pharmacovigilance 21: 1 2
19. Ahmad SR, Wolfe SM (1995) Cisapride and torsades de pointes. Lancet 345: 508
20. Wilton L, Inman W, Kubota K, Pearce G, Skipp M (1993) PEM Report No 9: Omeprazole. Pharmacoepidemiol Drug Safety 2: 473-498